These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 25137170)

  • 41. Pure small cell recurrent prostate cancer developing syndrome of inappropriate antidiuretic hormone secretion.
    Peverelli G; Grassi P
    Tumori; 2017 Nov; 103(Suppl. 1):e56-e59. PubMed ID: 28623637
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Urea therapy for inappropriate antidiuretic hormone secretion from tuberculous meningitis.
    Decaux G; Unger J; Mockel J
    JAMA; 1980 Aug; 244(6):589-90. PubMed ID: 7392157
    [No Abstract]   [Full Text] [Related]  

  • 43. [A case of SIADH due to pancreatic cancer was improved by tolvaptan].
    Matsuyama S; Ueo T; Ozawa T; Matsumoto A; Minami R; Kimura Y; Takeda Y; Okano A; Kusumi F; Ohana M
    Nihon Shokakibyo Gakkai Zasshi; 2022; 119(2):172-178. PubMed ID: 35153267
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Response to 'How we define hyponatremia?'.
    Grant P; Ayuk J; Bouloux PM; Cohen M; Cranston I; Murray RD; Rees A; Thatcher N; Grossman A
    Eur J Clin Invest; 2015 Nov; 45(11):1218. PubMed ID: 26343423
    [No Abstract]   [Full Text] [Related]  

  • 45. Blood urea nitrogen as a marker of the acute response to addition of tolvaptan to standard therapy in patients hospitalized for acute heart failure syndromes.
    Kajimoto K; Abe T
    Int J Cardiol; 2014 Dec; 177(2):589-91. PubMed ID: 25200849
    [No Abstract]   [Full Text] [Related]  

  • 46. [A case of venlafaxine-induced syndrome of inappropriate ADH secretion (SIADH) - treatment with tolvaptan].
    Meyer I; Frank D; Janssens U
    Dtsch Med Wochenschr; 2012 May; 137(21):1096-9. PubMed ID: 22588654
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tolvaptan for hyponatremia.
    Ozkan C; Kirkpantur A; Arici M
    N Engl J Med; 2007 Mar; 356(9):962; author reply 962-3. PubMed ID: 17338053
    [No Abstract]   [Full Text] [Related]  

  • 48. Tolvaptan for hyponatremia.
    Weise WJ; Rimmer JM; Hood VL
    N Engl J Med; 2007 Mar; 356(9):961; author reply 962-3. PubMed ID: 17329708
    [No Abstract]   [Full Text] [Related]  

  • 49. An economic analysis of tolvaptan compared with fluid restriction among hospitalized patients with hyponatremia.
    Ramamohan V; Mladsi D; Ronquest N; Kamat S; Boklage S
    Hosp Pract (1995); 2017 Aug; 45(3):111-117. PubMed ID: 28449624
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Improving care and outcomes of inpatients with syndrome of inappropriate antidiuresis (SIAD): a prospective intervention study of intensive endocrine input vs. routine care.
    Tzoulis P; Carr H; Bagkeris E; Bouloux PM
    Endocrine; 2017 Feb; 55(2):539-546. PubMed ID: 27837439
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Urea for management of the syndrome of inappropriate secretion of ADH: A systematic review.
    de Solà-Morales O; Riera M
    Endocrinol Nutr; 2014 Nov; 61(9):486-92. PubMed ID: 24954885
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Urea as therapeutic option for the treatment of the syndrome of inappropriate antidiuretic hormone secretion].
    Varsavsky M; Quesada Charneco M; Rozas Moreno P
    Med Clin (Barc); 2011 Jul; 137(5):237-8. PubMed ID: 21145071
    [No Abstract]   [Full Text] [Related]  

  • 53. Successful treatment of ifosfamide-induced hyponatremia with AVP receptor antagonist without interruption of hydration for prevention of hemorrhagic cystitis.
    Glezerman IG
    Ann Oncol; 2009 Jul; 20(7):1283-5. PubMed ID: 19542534
    [No Abstract]   [Full Text] [Related]  

  • 54. Use of conivaptan for refractory syndrome of inappropriate secretion of antidiuretic hormone in a pediatric patient.
    Peters S; Kuhn R; Gardner B; Bernard P
    Pediatr Emerg Care; 2013 Feb; 29(2):230-2. PubMed ID: 23546432
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The V2 receptor antagonist tolvaptan raises cytosolic calcium and prevents AQP2 trafficking and function: an in vitro and in vivo assessment.
    Tamma G; Di Mise A; Ranieri M; Geller A; Tamma R; Zallone A; Valenti G
    J Cell Mol Med; 2017 Sep; 21(9):1767-1780. PubMed ID: 28326667
    [TBL] [Abstract][Full Text] [Related]  

  • 56. 'Dos and don'ts' in the management of hyponatremia.
    Aylwin S; Burst V; Peri A; Runkle I; Thatcher N
    Curr Med Res Opin; 2015; 31(9):1755-61. PubMed ID: 26173050
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Symptomatic therapy of SIADH in small cell lung cancer by tolvaptan].
    Schnaiter A; Hiddemann W
    Dtsch Med Wochenschr; 2014 Oct; 139(41):2077-9. PubMed ID: 25268207
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tolvaptan for the Syndrome of Inappropriate Secretion of Antidiuretic Hormone: Is the Dose Too High?
    Sterns RH
    Am J Kidney Dis; 2018 Jun; 71(6):763-765. PubMed ID: 29801549
    [No Abstract]   [Full Text] [Related]  

  • 59. [Effect of tolvaptan on ascites due to malignancy].
    Mitsuhashi N; Nemoto S; Satoh Y; Aoki Y; Teranaka R; Sasaki K; Shimazaki R; Ueda A; Nishino H; Akiyama T; Hosokawa I; Yoichi T; Kawamoto J; Kuboki S; Yoshitomi H; Kato A; Shimizu Y; Ohtsuka M; Shimizu H; Miyazaki M
    Gan To Kagaku Ryoho; 2015 Feb; 42(2):201-5. PubMed ID: 25743139
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment of the syndrome of inappropriate secretion of antidiuretic hormone by long loop diuretics.
    Decaux G
    Nephron; 1983; 35(2):82-8. PubMed ID: 6621759
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.